Thus, we speculated that CDK1, CDK5, CDC20, CCNA2, CCNB1 and CCNB2 might be novel prognostic biomarkers and promising immunity therapeutic targets for HCC patients. Here, CCNA2 is linked to hepatocellular carcinoma.